OptimizeRx Corp. Files 8-K on Financials
Ticker: OPRX · Form: 8-K · Filed: Nov 13, 2024 · CIK: 1448431
| Field | Detail |
|---|---|
| Company | Optimizerx CORP (OPRX) |
| Form Type | 8-K |
| Filed Date | Nov 13, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-K
TL;DR
OptimizeRx filed an 8-K on Nov 13, 2024, for financial updates. Details TBD.
AI Summary
OptimizeRx Corp. filed an 8-K on November 13, 2024, reporting on its results of operations and financial condition, and filing financial statements and exhibits. The filing does not contain specific financial figures or operational details within the provided text.
Why It Matters
This filing indicates OptimizeRx Corp. is providing updates on its financial performance and condition to the SEC, which is important for investors to monitor the company's health.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for financial reporting and does not inherently indicate new risks.
Key Players & Entities
- OptimizeRx Corp. (company) — Registrant
- November 13, 2024 (date) — Date of Report
- Nevada (jurisdiction) — State of incorporation
- 260 Charles Street, Suite 302, Waltham, MA 02453 (address) — Principal executive offices
FAQ
What specific financial information is being reported in this 8-K filing?
The provided text indicates the filing pertains to 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits,' but does not detail the specific figures or content of these reports.
When was this 8-K report filed with the SEC?
The report was filed on November 13, 2024.
What is the exact name of the company filing this report?
The exact name of the registrant is OptimizeRx Corporation.
In which state was OptimizeRx Corporation incorporated?
OptimizeRx Corporation was incorporated in Nevada.
What is the address of OptimizeRx Corporation's principal executive offices?
The address of the principal executive offices is 260 Charles Street, Suite 302, Waltham, MA 02453.
Filing Stats: 514 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-11-13 16:10:27
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 Par Value OPRX The Nasdaq Capital M
Filing Documents
- ea0221012-8k_optimize.htm (8-K) — 24KB
- ea022101201ex99-1_optimize.htm (EX-99.1) — 126KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- 0001213900-24-097468.txt ( ) — 340KB
- oprx-20241113.xsd (EX-101.SCH) — 3KB
- oprx-20241113_lab.xml (EX-101.LAB) — 33KB
- oprx-20241113_pre.xml (EX-101.PRE) — 22KB
- ea0221012-8k_optimize_htm.xml (XML) — 4KB
02 Results of Operations and Financial
Item 2.02 Results of Operations and Financial Condition. On November 13, 2024, OptimizeRx Corporation issued a press release announcing its financial results for the third quarter ended September 30, 2024. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. The information in this Item 2.02 and Exhibit 99.1 attached hereto are furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. Exhibit Number Description 99.1 Press Release, dated November 13, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. OPTIMIZERX CORPORATION Date: November 13, 2024 By: /s/ Edward Stelmakh Name: Edward Stelmakh Title: Chief Financial Officer 2